This event is archived. Final snapshot from when the story concluded. View on Dashboard
Events / Lantheus Holdings Faces Securities Lawsuit
Regulatory securities lawsuit

Lantheus Holdings Faces Securities Lawsuit

Analysis based on 8 articles · First reported Feb 01, 2026 · Last updated Mar 02, 2026

Sentiment
-30
Attention
2
Articles
8
Market Impact
Direct
Live prominence charts, article sentiment distribution, and event development timeline available on the NewsDesk Dashboard
Market Impact

The market is negatively impacted by the news of a securities class action lawsuit and investigation against Lantheus Holdings, Inc., leading to concerns about its financial performance and corporate governance. This event could signal increased scrutiny for pharmaceutical companies regarding product revenue forecasting and regulatory compliance.

Pharmaceuticals Legal Services
Event Summary

Lantheus Holdings, Inc. is facing a securities class action lawsuit and an investigation by Kahn Swick & Foti, LLC. This stems from an 8% year-over-year decline in revenue for its flagship product, Piflufolastat (18F), and subsequent cuts to its full-year guidance, along with widespread contract renegotiations and account losses. The lawsuit alleges that Lantheus Holdings and its executives failed to disclose material information and underestimated the pricing and reimbursement risks associated with a United States===Centers for Medicare & Medicaid Services rule change. Kahn Swick & Foti, LLC is investigating whether the company's officers and/or directors breached their fiduciary duties or violated federal securities laws.

Key Actions
95 Lantheus Holdings sued in securities class action lawsuit
90 Lantheus Holdings disclosed revenue decline and guidance cuts
85 Kahn Swick & Foti commenced investigation Lantheus Holdings
70 United States===Centers for Medicare & Medicaid Services implemented new reimbursement rule
Entities Involved
stock
Lantheus Holdings
Lantheus Holdings is facing a securities class action lawsuit and an investigation by Kahn Swick & Foti, LLC due to an 8% decline in Piflufolastat (18F) revenue and cuts to its full-year guidance. The lawsuit alleges that the company failed to disclose material information and underestimated pricing and reimbursement risks related to a United States===Centers for Medicare & Medicaid Services rule.
Importance 100 Sentiment -70
priv
Kahn Swick & Foti
Kahn Swick & Foti, LLC has commenced an investigation into Lantheus Holdings, Inc. regarding potential breaches of fiduciary duties by its officers and/or directors and violations of state or federal laws. The firm is actively seeking information from long-term holders of Lantheus Holdings shares.
Importance 80 Sentiment 20
govactor
United States===Centers for Medicare & Medicaid Services
A rule by the United States===Centers for Medicare & Medicaid Services, shifting hospital reimbursement for Piflufolastat (18F) from Average Sales Price to Mean Unit Cost rates, is cited as a key factor in the pricing and reimbursement risks faced by Lantheus Holdings.
Importance 40 Sentiment 0
per
Charles Foti
Charles C. Foti, Jr., a partner at Kahn Swick & Foti, LLC, announced the firm's investigation into Lantheus Holdings, Inc. His involvement highlights the legal expertise leading the investigation.
Importance 30 Sentiment 10
Relationships
Kahn Swick & Foti related ↔ Lantheus Holdings
Charles Foti related ↔ Kahn Swick & Foti
NEWSDESK
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About NewsDesk

NewsDesk is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.newsdesk.dev.